Low-dose docetaxel, estramustine and prednisolone combination chemotherapy for castration-resistant prostate cancer

  • Authors:
    • Mayura Nakano
    • Sunao Shoji
    • Taro Higure
    • Masayoshi Kawakami
    • Tetsuro Tomonaga
    • Toshiro Terachi
    • Toyoaki Uchida
  • View Affiliations

  • Published online on: March 24, 2016     https://doi.org/10.3892/mco.2016.830
  • Pages: 942-946
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The objective of this study was to report our experience with weekly low-dose docetaxel (DOC) chemotherapy for patients with castration-resistant prostate cancer (CRPC). From 2007 to 2014, 39 consecutive patients received weekly low‑dose DOC; the oncological effectiveness, side effects and tolerability were prospectively analyzed. The median patient age, serum prostate-specific antigen (PSA) level and Gleason score at diagnosis of prostate cancer were 71 years (range, 55‑83 years), 187 ng̸ml (range, 2.0‑1711 ng̸ml) and 8 (range, 5‑10), respectively. The median number of cycles of DOC was 7 (range, 1‑45 cycles). Of the 39 patients, the PSA level decreased by >50% in 13 (33%). In the multivariate analysis of prediction of patient overall survival, a decrease of the PSA level to <50% was a significant predictor (hazard ratio = 6.913; 95% confidence interval: 1.147‑41.669; P=0.035). The median cancer‑specific overall survival from the diagnosis of CRPC was 16.7 months (range, 2‑54 months). Grade 3 toxicities were observed in 5 patients (13%); specifically, limb edema, nausea and hepatic disorders were detected in 2 (5%), 2 (5%) and 1 patient (3%), respectively. Treatment‑related death (grade 5) occurred in 1 patient due to interstitial pneumonia after two courses of chemotherapy. The chemotherapy was completed in the majority of the patients (n=37, 94.8%) in the outpatient department, without interruption. These findings suggest that weekly low‑dose DOC is feasible and safe for selected patients with CRPC, without treament with novel agents, such as abiraterone, enzalutamide and cabazitaxel.
View Figures
View References

Related Articles

Journal Cover

June 2016
Volume 4 Issue 6

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Nakano, M., Shoji, S., Higure, T., Kawakami, M., Tomonaga, T., Terachi, T., & Uchida, T. (2016). Low-dose docetaxel, estramustine and prednisolone combination chemotherapy for castration-resistant prostate cancer. Molecular and Clinical Oncology, 4, 942-946. https://doi.org/10.3892/mco.2016.830
MLA
Nakano, M., Shoji, S., Higure, T., Kawakami, M., Tomonaga, T., Terachi, T., Uchida, T."Low-dose docetaxel, estramustine and prednisolone combination chemotherapy for castration-resistant prostate cancer". Molecular and Clinical Oncology 4.6 (2016): 942-946.
Chicago
Nakano, M., Shoji, S., Higure, T., Kawakami, M., Tomonaga, T., Terachi, T., Uchida, T."Low-dose docetaxel, estramustine and prednisolone combination chemotherapy for castration-resistant prostate cancer". Molecular and Clinical Oncology 4, no. 6 (2016): 942-946. https://doi.org/10.3892/mco.2016.830